Sign In
Buy CRSP
$46.99
-0.790 (-1.65%)
At Close: Jul 20, 2026
Crispr Therapeutics Q4 Earnings Review: Ignore The Lack Of Revenues, Buy The Future
11:06am, Thursday, 13'th Feb 2025
Crispr Therapeutics AG reported significant revenue declines in Q4 and FY24 due to reduced collaboration revenues, but maintains strong financial health with $298m cash and $1.6bn in marketable securi
Why CRISPR Therapeutics Stock Was a Massive Winner on Wednesday
06:37pm, Wednesday, 12'th Feb 2025
On Hump Day, investors piled into CRISPR Therapeutics (CRSP 9.29%) stock, sending its price more than 9% higher at the trading session's close. They were highly encouraged by the specialized healthcar
CRISPR Therapeutics Q4 Earnings and Revenues Surpass Estimates
10:36am, Wednesday, 12'th Feb 2025
CRSP reports encouraging fourth-quarter results. The commercial launch of the first CRISPR-based gene therapy, Casgevy, is progressing well.
CRISPR Therapeutics AG (CRSP) Reports Q4 Loss, Tops Revenue Estimates
06:12pm, Tuesday, 11'th Feb 2025
CRISPR Therapeutics AG (CRSP) came out with a quarterly loss of $0.44 per share versus the Zacks Consensus Estimate of a loss of $1.15. This compares to earnings of $1.10 per share a year ago.
CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results
04:01pm, Tuesday, 11'th Feb 2025
-2025 is poised to be a catalyst-rich year with key updates across several programs- -Ongoing launch of CASGEVY ® continues to gain momentum; new cell patient collection initiations expected to signi
Investing $1,000 in These 3 Beaten-Down Stocks Could Be a Brilliant Move
06:15am, Monday, 10'th Feb 2025
Investing in stocks that aren't performing well can be a good move, but only if there are good reasons to think they will recover. That isn't the case for many companies that have lagged broader equit
CRISPR Therapeutics Stock Before Q4 Earnings: To Buy or Not to Buy?
10:16am, Friday, 07'th Feb 2025
On CRSP's fourth-quarter 2024 earnings call, investors' focus will likely be on the sales figure of Casgevy, its first marketed product.
CRISPR Therapeutics AG (CRSP) Guggenheim SMID Cap Biotech Conference (Transcript)
04:16pm, Wednesday, 05'th Feb 2025
CRISPR Therapeutics AG (NASDAQ:CRSP ) Guggenheim SMID Cap Biotech Conference Transcript February 6, 2025 2:00 PM ET Company Participants Samarth Kulkarni - Chief Executive Officer Conference Call Part
Crispr Therapeutics: Why I've Become Even More Bullish (Rating Upgrade)
03:48pm, Wednesday, 05'th Feb 2025
Crispr Therapeutics AG's partnership with Vertex Pharmaceuticals offers financial support, mentorship, and validation, enhancing Crispr's approach and technology. Despite slower-than-expected Casgevy
Why CRISPR Therapeutics AG (CRSP) Outpaced the Stock Market Today
07:05pm, Tuesday, 04'th Feb 2025
In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $40.49, marking a +1.23% move from the previous day.
Are These 5 Biotech Stocks Set to Beat Q4 Earnings Estimates?
08:45am, Monday, 03'rd Feb 2025
Let us look at some biotech stocks, AMGN, CRSP, MRNA, SRPT and VRTX, which are poised to beat on fourth-quarter earnings.
CRISPR Therapeutics AG (CRSP) Declines More Than Market: Some Information for Investors
06:57pm, Wednesday, 29'th Jan 2025
In the closing of the recent trading day, CRISPR Therapeutics AG (CRSP) stood at $41.21, denoting a -1.44% change from the preceding trading day.
DeepSeek AI picks 2 stocks to buy and hold forever
10:44am, Monday, 27'th Jan 2025
Chinese-based generative artificial intelligence (AI) start-up DeepSeek is dominating conversations in technology and stock markets due to its performance, reportedly rivaling dominant players such as
CRISPR Therapeutics AG (CRSP) Sees a More Significant Dip Than Broader Market: Some Facts to Know
07:06pm, Friday, 24'th Jan 2025
CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $43.42, moving -1.83% from the previous trading session.
CRISPR Therapeutics (CRSP) Moves 6.5% Higher: Will This Strength Last?
09:31am, Thursday, 23'rd Jan 2025
CRISPR Therapeutics (CRSP) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price
